Biotech firm Biogen Idec (BIIB) has put itself on the block, another victim of shareholder activist by Carl Icahn. The company said that several firms had expressed interest. According to The Wall Street Journal, "Shares of the Cambridge, Mass., company traded at $69.43, up 3.4%, in 4 p.m. Nasdaq Stock Market composite trading Friday and after the company’s announcement jumped to $81.60 in after-hours trading."
Not a bad gain for a day. That puts the company’s market cap at over $23 billion
Mr. Icahn has suggested the best buy would me a mega-pharmaceutical company.
Biogen has forecast 2007 earnings of about $600 million. Analysts are predicting about $3.1 billion in revenue.
Biogen is growing fairly quickly, but selling biotech drugs can be a risky and competitive business. The FDA can halt trials and block sales at the drop of a hat.
The price tag, at over $82 a share, or about 8x, is, frankly, too rich. The credit environment makes the a deal even more dicey.
Mr. Icahn may want to make money, but, at these prices, a buyer won’t
Douglas A. McIntyre
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
